Loading the session
Loading the session
Loading instrument
$9.05
+0.33%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:30 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: −9.4% (SPY −1.6%, XLK −12.6%). 3 months: +74.1% (SPY −0.4%, XLK −5.1%). 1 year: +34.8% (SPY +13.6%, XLK +20.1%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: SENS, SPY and XLK · as of 4 Nov 2026
4.9M shares were sold short at the 15 Oct 2026 settlement, 11.7% of the 41.8M shares outstanding; covering them would take 7.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $9.02 was 1.4% below its 50-day average ($9.15) and 24.8% above its 200-day average ($7.23). It has closed above the 200-day for 63 sessions, since 7 Aug 2026. The 50-day average crossed above the 200-day on 3 Sep 2026, 43 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Closed at $9.02 on 4 Nov 2026: 15.2% below the 52-week high of $10.64 (30 Sep 2026) and 88.3% above the low of $4.79 (23 Jul 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.
August 7, 2026
+36.31%January 10, 2025
+80.62%February 11, 2022
−33.70%